COPENHAGEN, Denmark, July 16,
2024 /PRNewswire/ -- Synamics Therapeutics, a
groundbreaking AI-driven drug discovery startup dedicated to
combating drug resistance in cancer, proudly announces a lead
investment in its pre-seed round, from two prominent figures in the
biotechnology industry. Steen Riisgaard and Per Falholt have backed
Synamics Therapeutics as lead investors. Riisgaard, former CEO of
Novozymes, member of the Novo Nordisk Foundation's board, and
esteemed biotech investor and Falholt, former Chief Scientific
Officer of Novozymes and current Chief Scientific Officer at
21st.BIO, bring their extensive expertise and shared passion for
innovation to the Danish biotech company.
Synamics Therapeutics leverages cutting-edge artificial
intelligence technology to develop novel therapies aimed at
overcoming drug resistance in cancer, a major challenge in modern
oncology. With the funding, Synamics will validate its drug design
platform, Dynaptive™.
"We are thrilled to welcome Per Falholt and Steen Riisgaard as
lead investors," stated Violet
Zahedi, co-founder and CEO of Synamics Therapeutics. "Their
support not only validates our technical approach but also
accelerates our mission to revolutionize cancer treatment. Their
expertise and guidance will be invaluable as we continue to
innovate and push the boundaries of what AI can achieve in drug
discovery."
Steen Riisgaard, an experienced biotech leader who played a
pivotal role in making Novozymes a world leader in industrial
enzymes, states: "Investing in Synamics Therapeutics aligns with my
commitment to advancing healthcare solutions. The startup's novel
approach to drug discovery has the potential to make a significant
impact on patients' lives, and I look forward to contributing to
their journey."
Per Falholt, who played a pivotal role in Novozymes' growth
journey and has helped launch over 100 biotech products, adds: "I
am excited to support Synamics Therapeutics in their efforts to
tackle one of the most pressing challenges in cancer treatment. The
team's rigorous approach and the impressive capabilities of their
AI-driven platform are truly inspiring."
The co-founding team at Synamics Therapeutics is committed to
making significant advancements in the fight against drug-resistant
cancers and to staying ahead of cancer's evolution, ensuring longer
and healthier lives for patients.
For more information, please contact:
Violet Zahedi
CEO and Co-Founder
Synamics Therapeutics
info@synamics.com
www.synamics.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/synamics-therapeutics/r/synamics-therapeutics--ai-driven-drug-discovery-startup--attracts-former-novozymes-executives-as-lea,c4014377
The following files are available for download:
https://mb.cision.com/Main/23275/4014377/2913877.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.com/news-releases/synamics-therapeutics-ai-driven-drug-discovery-startup-attracts-former-novozymes-executives-as-lead-investors-302198060.html
SOURCE Synamics Therapeutics